Apatinib combined with pemetrexed
Phase 2UNKNOWN 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Nonsmall Cell Lung Cancer
Conditions
Nonsmall Cell Lung Cancer
Trial Timeline
Nov 1, 2016 → Nov 1, 2018
NCT ID
NCT02974933About Apatinib combined with pemetrexed
Apatinib combined with pemetrexed is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Nonsmall Cell Lung Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT02974933. Target conditions include Nonsmall Cell Lung Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02974933 | Phase 2 | UNKNOWN |
Competing Products
7 competing products in Nonsmall Cell Lung Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pembrolizumab + Pemetrexed + Cisplatin + Carboplatin | AbbVie | Pre-clinical | 23 |
| SLC-391 + pembrolizumab | Merck | Phase 1/2 | 41 |
| Erlotinib | Roche | Pre-clinical | 23 |
| Crizotinib | Pfizer | Phase 2 | 51 |
| Nivolumab | Bristol Myers Squibb | Phase 2 | 51 |
| Immune checkpoint inhibitors or docetaxel | Novocure | Phase 3 | 72 |
| Pemetrexed + Carboplatin + demcizumab | Mereo BioPharma | Phase 2 | 44 |